Clinirx Research Profile
Key Indicators
- Authorised Capital ₹ 20.05 Cr
as on 16-11-2024
- Paid Up Capital ₹ 6.45 Cr
as on 16-11-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -4.87%
(FY 2023)
- Profit -154.40%
(FY 2023)
- Ebitda -74.04%
(FY 2023)
- Net Worth -20.02%
(FY 2023)
- Total Assets -7.76%
(FY 2023)
About Clinirx Research
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 20.05 Cr and a paid-up capital of Rs 6.45 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Clinirx Research Private Limited India is Nayantika as COMPANY SECRETARY. Pawan Rustagi, Sujit Kumar, and Shiv Issar serve as directors at the Company.
- CIN/LLPIN
U85110WB2004PTC098498
- Company No.
098498
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2004
- Date of AGM
29 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Clinirx Research?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nayantika | Company Secretary | 03-Sep-2024 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujit Kumar  | Director | 07-May-2004 | Current |
| Pawan Rustagi | Director | 15-Jun-2013 | Current |
| Shiv Issar | Director | 20-May-2019 | Current |
Financial Performance and Corporate Structure Insights of Clinirx Research.
Clinirx Research Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.87% decrease. The company also saw a substantial fall in profitability, with a 154.4% decrease in profit. The company's net worth observed a substantial decline by a decrease of 20.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clinirx Research?
In 2023, Clinirx Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clinirx Research?
Clinirx Research has a workforce of 52 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clinirx Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clinirx Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
